Trametinib Shows Similar Benefit to Docetaxel in Previously Treated NSCLC

Share this content:
Trametinib showed similar survival and response as docetaxel in previously treated KRAS mutation-positive NSCLC.
Trametinib showed similar survival and response as docetaxel in previously treated KRAS mutation-positive NSCLC.

According to a recent study published online in the journal Annals of Oncology, researchers have found that trametinib, a selective allosteric MEK1/MEK2 inhibitor, showed similar progression-free survival and response rate as docetaxel in patients with previously treated KRAS mutation-positive non-small cell lung cancer (NSCLC).

For the phase II study, researchers sought to compare trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy.

They enrolled 129 patients withKRAS-mutant NSCLC and randomly assigned them 2:1 to receive trametinib 2mg orally once daily or docetaxel 75mg/m2 IV every 3 weeks.

RELATED: Tecemotide May Be Effective in NSCLC with Concurrent Chemoradiotherapy

Results showed that the median progression-free survival was 12 weeks in the trametinib group and 11 weeks in the docetaxel group (HR = 1.14; 95% CI: 0.75 - 1.75; P = 0.5197).

Although the overall survival data are immature, the median overall survival thus far was 8 months in the trametinib group and was not reached in the docetaxel group (HR = 0.97; 95% CI: 0.52 - 1.83; P = 0.934).

Twelve percent of patients in the trametinib arm achieved partial responses compared with 12% in the docetaxel arm (P = 1.0000).

Reference

  1. Blumenschein G, Smit EF, Planchard D, et al. A randomized phase 2 study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small cell lung cancer (NSCLC).Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv072.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters